Immunization with rP22 induces protective immunity against Schistosoma mansoni: Effects on granuloma down-modulation and cytokine production

Immunology Letters

Volumn 141, Issue 1, 2011, Pages 123-133

  Rezende, Cíntia M F ^a   Silva, Marina R ^a   Santos, íria G D ^a   Silva, Gerluza A B ^a   Gomes, Dawidson A ^a   Goes, Alfredo M ^a  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

Author keywords

Cytokine profile; Granuloma down modulation; Recombinant rP22; Schistosoma mansoni; Vaccine

Indexed keywords

COMPLEMENTARY DNA; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 4; RECOMBINANT PROTEIN P22; SCHISTOSOMA VACCINE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DNA LIBRARY; FEMALE; HISTOPATHOLOGY; IMMUNIZATION; IMMUNOMODULATION; INFECTION PREVENTION; INTERFERON PRODUCTION; LIVER FIBROSIS; LIVER GRANULOMA; MIRACIDIUM; MOLECULAR CLONING; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN ISOLATION; PROTEIN LOCALIZATION; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; WORM EGG;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; FEMALE; GRANULOMA; HELMINTH PROTEINS; HUMANS; HYPERSENSITIVITY; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-4; LIVER; MICE; MICE, INBRED C57BL; PUBLIC HEALTH; RABBITS; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VACCINES;

EID: 80955142609     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.09.003     Document Type: Article

References (49)

1. King C.H. Toward the elimination of schistosomiasis. N Engl J Med 2009, 360:106-109.
2. van der Werf M.J., de Vlas S.J., Brooker S., Looman C.W.N., Nagelkerke N.J.D., Habbema J.D.F., et al. Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Trop 2003, 86:125-139.
3. Steinmann P., Keiser J., Bos R., Tanner M., Utzinger J. Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 2006, 6:411-425.
4. Harder A. Chemotherapeutic approaches to schistosomes: current knowledge and outlook. Parasitol Res 2002, 88:395-397.
5. Fenwick A., Webster J.P. Schistosomiasis: challenges for control, treatment and drug resistance. Curr Opin Infect Dis 2006, 19:577-582.
6. Matthews K.R. Controlling and coordinating development in vector-transmitted parasites. Science 2011, 331:1149-1153.
7. Scientific working group on schistosomiasis: report of the scientific working group meeting 2005, WHO, World Health Organization, Geneve.
8. Bergquist R. Prospects for schistosomiasis vaccine development. TDR News; 2004.
9. Capron A., Riveau G., Bartley P., McManus D. Prospects for A schistosome vaccine. Curr Drug Targets Immune End Metab Disord 2002, 2:281-290.
10. Vignali D.A., Bickle Q.D., Cobbold S., Waldmann H., Taylor M.G. A role for CD4+ but not CD8+ T cells in immunity to Schistosoma mansoni induced by 20krad-irradiated and Ro 11-3128-terminated infections. Immunology 1989, 67:466-472.
11. Smythies L., Coulson P., Wilson R. Monoclonal antibody to IFN-gamma modifies pulmonary inflammatory responses and abrogates immunity to Schistosoma mansoni in mice vaccinated with attenuated cercariae. J Immunol 1992, 149:3654-3658.
12. Wilson R., Coulson P., Betts C., Dowling M., Smythies L. Impaired immunity and altered pulmonary responses in mice with a disrupted interferon-gamma receptor gene exposed to the irradiated Schistosoma mansoni vaccine. Immunology 1996, 87:275-282.
13. Jankovic D., Wynn T.A., Kullberg M.C., Hieny S., Caspar P., James S., et al. Optimal vaccination against Schistosoma mansoni requires the induction of both B Cell- and IFN-γ-dependent effector mechanisms. J Immunol 1999, 162:345-351.
14. Boros D.L., Whitfield J.R. Endogenous IL-10 regulates IFN-(and IL-5 cytokine production and the granulomatous response in Schistosomiasis mansoni-infected mice. Immunology 1998, 94:481-487.
15. Dewals B., Hoving J.C., Horsnell W.G., Brombacher F. Control of Schistosoma mansoni egg-induced inflammation by IL-4-responsive CD4+ CD25- CD103+ Foxp3- cells is IL-10-dependent. Eur J Immunol 2010, 40:2837-2847.
16. Zouain C.S., Gustavson S., Oliveira S.C., Azevedo V., Alves J.B., Goes A.M. The role of IL-10 and IgG1 in the protection and granulomatous response in Schistosoma mansoni P24-immunized mice. Vaccine 2000, 19:1218-1224.
17. Stadecker M.J., Hernandez H.J. The immune response and immunopathology in infection with Schistosoma mansoni: a key role of major egg antigen Sm-p40. Parasite Immunol 1998, 20:217-221.
18. Hirsch C., Zouain C., Alves J., Goes A.M. Induction of protective immunity and modulation of granulomatous hypersensitivity in mice using PIII, an anionic fraction of Schistosoma mansoni adult worm. Parasitology 1997, 115:21-28.
19. Gustavson S., Zouain C.S., Alves J.B., Leite M.F., Goes A.M. Modulation of granulomatous hypersensitivity against Schistosoma mansoni eggs in mice vaccinated with culture-derived macrophages loaded with PIII. Parasitol Int 2002, 51:259-269.
20. Hirsch C., Goes A.M. Characterization of fractionated Schistosoma mansoni soluble adult worm antigens that elicit human cell proliferation and granuloma formation in vitro. Parasitology 1996, 112:529-535.
21. Marques H.H., Zouain C.S., Torres C.B., Oliveira J.S., Alves J.B., Goes A.M. Protective effect and granuloma down-modulation promoted by RP44 antigen a fructose 1,6 bisphosphate aldolase of Schistosoma mansoni. Immunobiology 2008, 213:437-446.
22. Francis P., Bickle Q. Cloning of a 21.7-kDa vaccine-dominant antigen gene of Schistosoma mansoni reveals an EF hand-like motif. Mol Biochem Parasitol 1992, 50:215-224.
23. Makarova E., Goes T.S., Marcatto A.L.M., Leite M.F., Goes A.M. Serological differentiation of acute and chronic schistosomiasis using Schistosoma mansoni recombinant protein RP26. Parasitol Int 2003, 52:269-279.
24. Geer L.Y., Domrachev M., Lipman D.J., Bryant S.H. CDART: protein homology by domain architecture. Genome Res 2002, 12:1619-1623.
25. Cardoso F.C., Macedo G.C., Gava E., Kitten G.T., Mati V.L., de Melo A.L., et al. Schistosoma mansoni tegument protein Sm29 is able to induce a Th1-type of immune response and protection against parasite infection. PLoS Negl Trop Dis 2008, 2:e308.
26. Farias L.P., Cardoso F.C., Miyasato P.A., Montoya B.O., Tararam C.A., Roffato H.K., et al. Schistosoma mansoni stomatin like protein-2 is located in the tegument and induces partial protection against challenge infection. PLoS Negl Trop Dis 2010, 4:e597.
27. Tran M.H., Pearson M.S., Bethony J.M., Smyth D.J., Jones M.K., Duke M., et al. Tetraspanins on the surface of Schistosoma mansoni are protective antigens against schistosomiasis. Nat Med 2006, 12:835-840.
28. Chitsulo L., Loverde P., Engels D. Focus: schistosomiasis. Nat Rev Micro 2004, 2:12-13.
29. Schneider M.C., Aguilera X.P., Barbosa da Silva J., Ault S.K., Najera P., Martinez J., et al. Elimination of neglected diseases in Latin America and the Caribbean: a mapping of selected diseases. PLoS Negl Trop Dis 2011, 5:e964.
30. Berriman M., Haas B.J., LoVerde P.T., Wilson R.A., Dillon G.P., Cerqueira G.C., et al. The genome of the blood fluke Schistosoma mansoni. Nature 2009, 460:352-358.
31. Zhou Y., Zheng H., Chen Y., Zhang L., Wang K., et al. The Schistosoma japonicum genome reveals features of host-parasite interplay. Nature 2009, 460:345-351.
32. Fitzsimmons C., McBeath R., Joseph S., Jones F., Walter K., Hoffmann K., et al. Factors affecting human IgE and IgG responses to allergen-like Schistosoma mansoni antigens: molecular structure and patterns of in vivo exposure. Int Arch Allergy Immunol 2007, 142:40-50.
33. Lopes D.O., Paiva L.F., Martins M.A., Cardoso F.C., Rajão M.A., Pinho J.M., et al. Sm21.6 a novel EF-hand family protein member located on the surface of Schistosoma mansoni adult worm that failed to induce protection against challenge infection but reduced liver pathology. Vaccine 2009, 27:4127-4135.
34. Braschi S., Curwen R.S., Ashton P.D., Verjovski-Almeida S., Wilson A. The tegument surface membranes of the human blood parasite Schistosoma mansoni: a proteomic analysis after differential extraction. Proteomics 2006, 6:1471-1482.
35. Jones M.K., Gobert G.N., Zhang L., Sunderland P., McManus D.P. The cytoskeleton and motor proteins of human schistosomes and their roles in surface maintenance and host-parasite interactions. Bioessays 2004, 26:752-765.
36. Van Hellemond J.J., Retra K., Brouwers J.F., van Balkom B.W., Yazdanbakhsh M., Shoemaker C.B., et al. Functions of the tegument of schistosomes: clues from the proteome and lipidome. Int J Parasitol 2006, 36:691-699.
37. Zhang W., Ahmad G., Torben W., Siddiqui A.A. Schistosoma mansoni antigen Sm-p80: prophylactic efficacy of a vaccine formulated in human approved plasmid vector and adjuvant (VR 1020 and alum). Acta Trop 2011, 118:142-151.
38. Wynn T.A., Hoffmann K.F. Defining a schistosomiasis vaccination strategy-is it really Th1 versus Th2?. Parasitol Today 2000, 16:497-501.
39. Hewitson J.P., Hamblin P.A., Mountford A.P. Immunity induced by the radiation-attenuated schistosome vaccine. Parasite Immunol 2005, 27:271-280.
40. Pearce E., Caspar P., Grzych J., Lewis F., Sher A. Downregulation of Th1 cytokine production accompanies induction of Th2 responses by a parasitic helminth, Schistosoma mansoni. J Exp Med 1991, 173:159-166.
41. Stadecker M.J., Asahi H., Finger E., Hernandez H.J., Rutitzky L.I., Sun J. The immunobiology of Th1 polarization in high-pathology schistosomiasis. Immunol Rev 2004, 201:168-179.
42. Pearce E.J., MacDonald A.S. The immunobiology of schistosomiasis. Nat Rev Immunol 2002, 2:499-511.
43. Wynn T.A., Cheever A.W., Williams M.E., Hieny S., Caspar P., Kühn R., et al. IL-10 regulates liver pathology in acute murine Schistosomiasis mansoni but is not required for immune down-modulation of chronic disease. J Immunol 1998, 160:4473-4480.
44. Wynn T.A., Cheever A.W. Cytokine regulation of granuloma formation in schistosomiasis. Curr Opin Immunol 1995, 7:505-511.
45. Abath F.G., Morais C.N., Montenegro C.E., Wynn T.A., Montenegro S.M. Immunopathogenic mechanisms in schistosomiasis: what can be learnt from human studies?. Trends Parasitol 2006, 22:85-91.
46. Fallon P.G., Richardson E.J., McKenzie G.J., McKenzie A.N.J. Schistosome infection of transgenic mice defines distinct and contrasting pathogenic roles for IL-4 and IL-13: IL-13 is a profibrotic agent. J Immunol 2000, 164:2585-2591.
47. Wilson M.S., Mentink-Kane M.M., Pesce J.T., Ramalingam T.R., Thompson R., Wynn T.A. Immunopathology of schistosomiasis. Immunol Cell Biol 2007, 85:148-154.
48. Hesse M., Piccirillo C.A., Belkaid Y., Prufer J., Mentink-Kane M., Leusink M., et al. The pathogenesis of schistosomiasis is controlled by cooperating IL-10-producing innate effector and regulatory T cells. J Immunol 2004, 172:3157-3166.
49. Mentink-Kane M.M., Cheever A.W., Thompson R.W., Hari D.M., Kabatereine N.B., Vennervald B.J., et al. IL-13 receptor α 2 down-modulates granulomatous inflammation and prolongs host survival in schistosomiasis. Proc Natl Acad Sci USA 2004, 101:586-590.